Life Science News

SELLAS Life Sciences Group (Nasdaq:SLS) announced that the sponsor-principal investigator, after taking into account that key clinical development objectives were met as well as other regulatory considerations, and in agreement with SELLAS, determined to terminate early the Phase 2b independent investigator-sponsored clinical trial (IST) of trastuzumab (Herceptin®) +/- nelipepimut-S (NeuVax™) in HER2 1+/2+ breast cancer …

SELLAS Life Sciences Group (Nasdaq:SLS) announced that the sponsor-principal investigator, after taking into account that key clinical development objectives were met as well as other regulatory considerations, and in agreement with SELLAS, determined to terminate early the Phase 2b independent investigator-sponsored clinical trial (IST) of trastuzumab (Herceptin®) +/- nelipepimut-S (NeuVax™) in HER2 1+/2+ breast cancer patients. In this Phase 2b study, Herceptin® was provided under a Clinical Trial Supply Agreement by Genentech, Inc.

As quoted in the press release:

The decision to early terminate this Phase 2b study was based in part on the previously announced recommendation of the independent Data Safety Monitoring Board (DSMB) to further advance the development of the NeuVax + Herceptin combination for the triple negative breast cancer (TNBC) patient population. Data from the Phase 2b has been submitted for presentation at a major medical conference that will take place during the second half of 2018.

“We wish to thank our patients and their families for their participation in this trial.  Based on data demonstrating that this combination therapy has the potential to become an important therapeutic option for TNBC patients facing a life-threatening disease and for whom current options in the adjuvant setting are extremely limited, we have determined, in consensus with SELLAS, to close out the current study,” stated COL (ret) George E. Peoples, MD, FACS, Founder and Director of Cancer Insight, LLC and study Principal Investigator. “We look forward to supporting SELLAS’ interactions and discussions with regulatory bodies.”

Click here to read the full press release.

MARKETS

Markets
TSX19456.71+202.15
TSXV635.41+15.65
DOW32529.63+332.04
S&P 5004072.430.00
NASD12162.59+130.17
ASX6889.70+66.50

COMMODITIES

Commodities
Gold1760.78+6.05
Silver19.98+0.04
Copper3.51+0.03
Palladium2081.03+5.03
Platinum896.40+7.39
Oil98.55+2.13
Heating Oil3.62+0.01
Natural Gas8.33+0.19

DOWNLOAD FREE REPORTS

×